Evaluation of metabolic response with F-18-FDG PET-CT in patients with advanced or recurrent thymic epithelial tumors

Background: Patients with advanced or recurrent thymic epithelial tumors (TETs) often need several consecutive lines of chemotherapy. The aim of this retrospective monocentric study was to test whether F-18-Fluorodeoxyglucose positron emission tomography-computed tomography (F-18-FDG PET-CT) is able to monitor standard chemotherapy efficacy in those patients and whether metabolic response correlates with morphovolumetric response as assessed by Response Evaluation Criteria in Solid Tumor (RECIST).